热门资讯> 正文
Bio-Path Holdings Reports Tumor Regression in Early Trial for Solid Tumors; Shares Jump Pre-Bell
2024-08-21 19:59
07:59 AM EDT, 08/21/2024 (MT Newswires) -- Bio-Path Holdings (BPTH) said Wednesday that a patient treated with a higher 90 mg/m2 dose in its Phase 1/1b clinical trial of BP1001-A for solid tumors showed tumor regression and stable disease.
The company also noted "continued patient progress" in its Phase 2 triple combination study of prexigebersen in acute myeloid leukemia.
Bio-Path said supportive safety and efficacy data from both studies validate the potential of its DNAbilize platform technology to treat high-risk cancer patients.
Shares of Bio-Path were up more than 19% in Wednesday's premarket activity.
Price: 1.8190, Change: +0.33, Percent Change: +22.08
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
